Outcomes Of Remote Pulmonary Artery Hemodynamic Monitoring In Heart Failure Patients With Atrial Fibrillation In Male And Female Population

Abstract

Introduction Pulmonary artery (PA) hemodynamic monitoring using CadioMEMS device has shown to decrease heart failure (HF) readmissions. Atrial fibrillation (AFib) and HF often coexist and AFib can itself cause variations in PA pressures. We studied the impact of remote PA hemodynamic monitoring in reducing HF readmissions in patients with Afib and HF in male and female population. Method Retrospective data was collected for patients with HF who had CardioMEMS device implanted based on FDA indications from April 2015 to August 2020. Data including number of all cause and HF hospitalizations, emergency department (ED) and HF clinic visits was collected for 1-year pre and 1-year post device implantation. Mortality data was collected at 1-year post-implantation. Analysis was done using the median and Kruskal-Wallis test for comparison between different age groups. Mortality was compared using Pearson's chi-squared test. Results CardioMEMS device was implanted in 177 patients during the study period. Of this population, 107 (60%) had AFib. There was a statistically significant decrease in overall mean HF admissions in Afib patients from 1.68 (± 1.34) to 0.63 (± 1.08), (63.1%) p<0.001 and mean HF ED visits 1.38 (± 1.40) to 0.57 (± 1.02), (58.7%) p<0.001 between 1-year pre and post implantation. But there was no statistically significant difference between male and female population in all-cause admissions, HF admissions, ED visits, ED HF visits, HF clinic visits along with mortality at 1-year post-implantation. Conclusion Remote PA hemodynamic monitoring decreases heart failure readmissions and ED visits in patients with AFib and HF and outcomes are similar in male and female population. Pulmonary artery (PA) hemodynamic monitoring using CadioMEMS device has shown to decrease heart failure (HF) readmissions. Atrial fibrillation (AFib) and HF often coexist and AFib can itself cause variations in PA pressures. We studied the impact of remote PA hemodynamic monitoring in reducing HF readmissions in patients with Afib and HF in male and female population. Retrospective data was collected for patients with HF who had CardioMEMS device implanted based on FDA indications from April 2015 to August 2020. Data including number of all cause and HF hospitalizations, emergency department (ED) and HF clinic visits was collected for 1-year pre and 1-year post device implantation. Mortality data was collected at 1-year post-implantation. Analysis was done using the median and Kruskal-Wallis test for comparison between different age groups. Mortality was compared using Pearson's chi-squared test. CardioMEMS device was implanted in 177 patients during the study period. Of this population, 107 (60%) had AFib. There was a statistically significant decrease in overall mean HF admissions in Afib patients from 1.68 (± 1.34) to 0.63 (± 1.08), (63.1%) p<0.001 and mean HF ED visits 1.38 (± 1.40) to 0.57 (± 1.02), (58.7%) p<0.001 between 1-year pre and post implantation. But there was no statistically significant difference between male and female population in all-cause admissions, HF admissions, ED visits, ED HF visits, HF clinic visits along with mortality at 1-year post-implantation. Remote PA hemodynamic monitoring decreases heart failure readmissions and ED visits in patients with AFib and HF and outcomes are similar in male and female population.